Biotage AB is committed to upholding a set of core values and a corporate philosophy that guide its operations. The company values innovation, excellence, and the pursuit of sustainable solutions for its customers. Biotage AB focuses on developing cutting-edge technology to support scientists and researchers in their pursuit of breakthroughs. With a customer-driven approach, the company aims to deliver reliable and high-quality products and services that meet the evolving needs of the scientific community. Additionally, Biotage AB prioritizes social responsibility by adhering to ethical practices, promoting diversity and inclusion, and minimizing its environmental impact.

Biotage AB is primarily present in several countries and regions worldwide. The company has a strong presence in Europe, including Sweden, where its headquarters are located. Biotage AB also has operations in other European countries such as Germany, United Kingdom, France, Italy, and Spain. Additionally, Biotage has established a significant presence in North America, particularly in the United States. With its global reach, Biotage AB is continually expanding its market presence and serving customers in diverse regions around the world.

Biotage AB has achieved several significant milestones. The company has successfully developed and introduced innovative solutions in the field of separation sciences, including purification systems, sample preparation, and analysis tools. It has also expanded its product portfolio by acquiring complementary technologies and businesses, thereby strengthening its market position. Biotage AB has demonstrated steady revenue growth and profitability over the years, reflecting its successful market strategies. Additionally, the company has fostered strong collaborations with leading research institutions and industry partners, enabling them to provide cutting-edge solutions to their customers. Biotage AB's dedication to innovation and customer satisfaction has propelled its success in the stock market.

Biotage AB is a well-established company in the field of life sciences and analytical chemistry. It was founded in 2003 and has since become a leading provider of tools and solutions for organic and analytical chemistry. Biotage AB specializes in the development and production of products used in research, drug discovery, and quality control applications. With a strong focus on innovation and customer satisfaction, Biotage AB offers a wide range of solutions, including purification systems, sample preparation, and analytical instruments. The company has a global presence, serving customers in various sectors such as pharmaceutical, biotechnology, and academia. Biotage AB continues to strive for excellence in delivering high-quality products and driving advancements in the field of life sciences.

The main competitors of Biotage AB in the market include Agilent Technologies Inc., Thermo Fisher Scientific Inc., and Shimadzu Corporation. These companies provide similar products and services in the field of analytical chemistry, separation science, and purification technologies. Biotage AB competes with these industry leaders by offering innovative solutions and a wide range of products such as chromatography systems, purification systems, and consumables. With its dedication to research and development, Biotage AB strives to stay competitive and deliver cutting-edge solutions that meet the needs of its customers.

Biotage AB is primarily active in the life sciences and pharmaceutical industries.

Biotage AB operates under a business model focused on providing innovative separation solutions for pharmaceutical, biotech, and academic research organizations. The company specializes in the development, manufacturing, and distribution of instruments, consumables, and software for analytical chemistry, medicinal chemistry, and process development. Biotage's products enable efficient sample preparation, purification, and analysis, leading to improved productivity and quality in various applications. With a strong emphasis on customer-driven solutions, Biotage aims to support researchers and industry professionals in their quest for reliable and efficient chemical analysis and purification techniques. Biotage AB remains dedicated to advancing science and delivering superior products to meet the evolving needs of the life sciences industry.

Biotage KGV ir 54,54.

Biotage KUV ir 6,51.

AlleAktien kvalitātes vērtējums Biotage ir 8/10.

gaidāmā Biotage apgrozījums ir 2,17 miljardi SEK.

gaidāmā Biotage peļņa ir 258,99 milj. SEK.

Biotage AB is a leading company in the field of separation technology and offers innovative solutions for the purification of chemical compounds in the pharmaceutical, biotechnological, and chemical industries, as well as in the food and environmental industries. The company Biotage specializes in three business areas: separation technology, analytical instruments, and consumer products. In the field of separation technology, Biotage offers a wide range of products, including solid phase extraction, flash chromatography, air particle removal, and ion exchange resins. These products are used in the chemical and biotechnological industries to separate and purify compounds. In the field of analytical instruments, Biotage produces high-performance chromatography systems, mass spectrometers, and spectroscopy systems. These instruments are used in scientific research and quality control in the pharmaceutical and biotechnological industries. In the field of consumer products, Biotage offers a wide range of products, including reagents, laboratory supplies, and consumables. The flagship product of the company in the field of separation technology is the Isolera™ Prime Flash Chromatograph. This instrument uses patented technology to perform fast and effective separations in the chemical and biotechnological industries. Biotage's top-of-the-line analytical instrument is the nau-MS™ system, which combines the performance of a mass spectrometer with the speed and efficiency of flash chromatography. The nau-MS™ system allows scientists and researchers to quickly and easily identify and quantify compounds in complex samples. Biotage also produces a wide range of portable GC-MS systems and TOF-MS systems, which are used in healthcare monitoring, environmental monitoring, forensic science, and the food industry. Biotage's products are used by leading companies in the pharmaceutical, biotechnological, and chemical industries, as well as in environmental monitoring and the food industry. Biotage's customers include Novartis, Pfizer, Merck, Johnson & Johnson, Roche, AstraZeneca, GlaxoSmithKline, and Sanofi. Biotage is headquartered in Uppsala, Sweden, and has offices and sales offices in North America, Europe, and Asia. The company has a strong presence in the United States, the largest market for separation technologies. In recent years, the company has expanded its product range through strategic acquisitions. In 2017, Biotage acquired the German flash chromatography specialist Interchim, and in 2019, it acquired the American company PhyNexus. These acquisitions have strengthened Biotage's position in the market for separation technology and analytical instruments. In conclusion, Biotage is a leading company in the field of separation technology and analytical instruments, providing a wide range of products and solutions for its customers. The company has a strong presence in the markets of the pharmaceutical, biotechnological, and chemical industries, as well as the environmental and food industries, and is on a growth trajectory through strategic acquisitions and global expansion.

Biotage izmaksā dividendes 1,55 SEK, kas tiek izmaksātas 1 reizes gadā.

Biotage izmaksā dividendes 1 reizes gadā.

Biotage ISIN ir SE0000454746.

Biotage WKN ir A0MNB5.

Biotage simbols ir BIOT.ST.

Pēdējo 12 mēnešu laikā Biotage maksāja dividendes 1,60 SEK apmērā. Tas atbilst aptuveni 0,84 % dividendes ražībai. Nākamajos 12 mēnešos Biotage plāno maksāt dividendes 1,75 SEK apmērā.

Biotage pašreizējā dividendu rentabilitāte ir 0,84 %.

Biotage maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos maijs, maijs, maijs, maijs.

Biotage pēdējo 8 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 1,75 SEK. Tas atbilst dividendes ražībai 0,92 %.

Biotage tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Biotage apmērā 1,6 SEK, kas tika izmaksāta 3.05.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.04.2024..

Pēdējās dividendes izmaksa notika 3.05.2024..

Gadā 2023, Biotage izmaksāja 1,55 SEK dividendes.

Biotage dividendes tiek izmaksātas SEK.